The Radiogenomics Consortium was established in November 2009. The scientific hypothesis underlying the development of the consortium is that a cancer patient's likelihood of developing toxicity to radiation therapy is influenced by common genetic variations, such as single nucleotide polymorphisms (SNPs).
The Consortium members undertake collaborative projects to identify SNPs associated with adverse effects following radiotherapy, share data and samples, perform meta-analyses, and work together to submit research grant applications.
In this video from 2010 (after the first meeting) Prof Catherine West speaks to ecancer tv about the radiogenomics consortium. Monday 19th of June the 9th Annual RGC meeting will take place in Barcelona, Spain and is hosted by Vall d’Hebron Institute of Oncology (VHIO).
Click here for the agenda (RGC meeting 2017)